

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,

Karachi

No.2/2/2003-F.Sec.

Dated: **31/12/2007**

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING-15-09-2007 TO BE PUBLISHED ON 01-01-2008-
IN THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1066/2007	10-9-2007 1. Muhammad Kamil. 2. Rashid Ali Siddiqui 3. Muhammad Ishaq Qaimkhani. PCSIR, Karachi Pakistan.	“A process for the preparation of antiperspirant lotion”
1067/2007	Astrazeneca AB. Sweden. Priority (26-01-2000 GB) Divisional.	“A method of producing a stabilized pharmaceutical composition comprising a pharmaceutically acceptable salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid”
1068/2007	N.V. Organon. USA. Priority (11-09-2006 USA)	“Quinazolinone and isoquinolinone acetamide derivatives”
1069/2007	Sanofi-Aventis. USA. Priority 11-09-2006 USA)	“Kinase inhibitor”
1070/2007	Glaxo Group Limited. United Kingdom. Priority (12-09-2006 USA)	“Pharmaceutical composition”
1071/2007	Otsuka Pharmaceutical Co. Ltd. Japan. Priority (30-04-2004 Japan) Divisional.	“Apharmaceutically acceptable salt of a 4-amino-5-cyanopyrimidine derivative”
1072/2007	Glaxo Group Limited. United Kingdom. Priority (11-09-2006 GB)	“Chemical compounds”
1073/2007	11-09-2007 Pailung Machinery Mill Co. Ltd.	“Corduroy fabric”

R.O.C.

1074/2007	Pailung Machinery Mill Co. Ltd. R.O.C.	“Yarn loop density adjustment apparatus for circular knitting machines”
1075/2007	Under the Boardwalk Properties 8 (Proprietary) Limited. South Africa. Priority (11-09-2006 South Africa)	“Apparatus and method for treating non-human mammals”
1076/2007	Bayer CropScience AG. Germany. Priority (15-09-2006 Germany)	“Oil based suspension concentrates”
1077/2007	Bayer HealthCare AG. Germany. Priority (12-09-2006 Germany)	“2-Phenoxynicotinic acid derivatives and use thereof”
1078/2007	Sanofi-Aventis. France. Priority (13-09-2006 Germany)	“Isoleucine derivatives as inhibitors of coagulation factor 1Xa”
1079/2007	Smithkline Beecham Corporation. USA. Priority (13-09-2006 USA)	“Methods for administering long-lasting hypoglycemic agents”
1080/2007	Sanofi-Aventis. France. Priority (13-09-2006 Germany)	“Tartrate derivatives as inhibitors of coagulation factor 1xa”
1081/2007	1. Mr. Syed Farhan Gilani. 2. Muhammad Afzal. Islamabad-Pakistan.	“Preg on”
1082/2007	1. Mr.Syed Farhan Gilani. 2. Muhammad Afzal. Islamabad-Pakistan.	“Gyno Vit”
1083/2007	1. Mr. Syed Farhan Gilani. 2. Muhammad Afzal. Islamabad-Pakistan.	“Preg Nil”

1084/2007	1. Mr. Syed Farhan Gilani. 2. Muhammad Afzal. Islamabad-Pakistan.	“PPL”
1085/2007	1. Mr. Syed Farhan Gilani. 2. Muhammad Afzal. Islamabad-Pakistan.	“Kor-c”
1086/2007	<u>12-09-2007</u> 1. Nida-Saleem. 2. Muhammad Kamran. 3. Zahida N. Umar. PCSIR, Karachi.	“Sweet Carrot Chips”
1087/2007	Pfizer Products Inc. USA. Priority (15-09-2006 USA)	“4-methylpyridopyrimidinone compounds”
1088/2007	Otsuka Pharmaceutical Co., Ltd. Japan. Priority (13-05-2005 Japan) Divisional.	“A pyrrolidine compound for use as a pharmaceutical”
1089/2007	Novartis AG. Switzerland. Priority (14-09-2006 EP)	“Organic compounds”
1090/2007	Basf Aktiengesellschaft. Germany. Priority (14-09-2006 USA)	“Pesticide composition”
1091/2007	<u>13-09-2007</u> Afton Chemical Corporation, USA (Priority 19-9-06 USA)	“Diesel fuel additives containing cerium or manganese and detergents”
1092/2007	1. AstraZeneca AB, Sweden 2. Targacept USA (Priority 15-9-06 USA)	“Therapeutic combinations 482”
1093/2007	Sanofi-Aventis France (Priority 21-9-06 France)	“Process for preparing n-alkyl naltrexone halides”

1094/2007	Novartis AG, Switzerland (Priority 15-9-06 EP)	“Organic compounds”
1095/2007	National Center of Excellence in Molecular Biology Lahore, Pakistan	“Development of 13-plex PCR system based on X-chromosome short tandem repeats (X-STRs) for determining blood relationship”
1096/2007	MOK-Siong Cheak, Steven Singapore (Priority 13-9-06 Singapore)	“System for generating brown gas and uses thereof”
	<u>14-9-2007</u>	
1097/2007	Syngenta Participations AG, Switzerland (Priority 09-10-06 USA)	“Pesticidal combinations”
1098/2007	Dr. Zafar Iqbal PCSIR, Karachi Pakistan	“Improved splitter”
	<u>15-9-2007</u>	
1099/2007	World Wide Stationery Manufacturing Company, Ltd. Hong Kong (Priority 02-3-07 USA)	“ Ring binder mechanism”
1100/2007	World Wide Stationery Manufacturing Company, Ltd. Hong Kong (Priority 06-4-07 USA)	“ Ring binder mechanism”
1101/2007	Bayer CropScience LP USA (Priority 25-9-06 USA)	“Cotton fiber length enhancement”
1102/2007	Vitae Pharmaceuticals, Inc. USA (Priority 18-9-06 USA)	“ Renin inhibitors and method of use thereof”
1103/2007	GeoBiotics LLC, USA (Priority 15-9-06 South Africa)	“Pre-treatment of feed to non-stirred surface ioreactor”



APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

451/96	Warner –Lambert Company, USA	“Crystalline [R- (R* , R*)]-2-(4-fluorophenyl) –β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)”
--------	------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(Co7D, 207/335)

139306

Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl) –β, δ-dihydroxy-5-(1-methylethyl) -3-phenyl-4- [(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form I, Form II, and Form IV are characterized by their X-ray powder diffraction and/or solid state KMR are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating

603/2002 Merck & Co., Inc.
USA

hyperlipidemia and hypercholesterolemia.

“Substituted tetrahydro-triazolo[4,3- α] pyrazine”

(INT: CL, Co7D, 241/42, Co7D, 487/04)

139307

The present invention is substituted tetrahydro-Triazolo [4, 3. α] pyrazine, directed to compound which are inhibitor of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitor") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.


700/2004 AstraZeneca
Sweden

“Pyrrole compound”

(INT: CL, Co7D, 207/323, Co7D, 401/12)

139308

Compound of formula (1) are described:



(1)

Pharmaceutical composition containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

445/2005 Khurram Irshad
P.E.C.H.S.
Shahrah-e-Faisal, Karachi,
Pakistan

“Industrial waste water treatment”
(Co2F, 11/06)

139309

This invention relates to an industrial water conduct plant, more particularly the Textile waste water treatment, which comprises the steps in the process firstly to homogenized the waste from different process before the treatment, then removing the suspended particles (sludge) by using the process of Dissolved Air Floatation, then the water goes through filtration process to remove majority of the remaining TSS which is required as UF feed limitations, which thereafter takes the water and removes higher molecular organics or majority of the BOD is removed at this stage. UF treated waste water is then feed in to RO unites, they remove 99% of TDS along with COD and BOD. RO water is supplied to dye house for reuse, while RO concentrate is drained.

754/2006 Merck & Co., Inc.
USA

“Salt of substituted tetrahydro-triazolo[4, 3-a]
pyrazine”

(INT: CL, Co7D, 241/42,)

139310

The present invention is substituted tetra hydro triazolo [4, 3, α] pyrazine compound which are inhibitor of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitor") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

XXXXXXXXXXXXXXXXXX